Clinical Trial Update: Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 to 17 Years [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and efficacy of Rifamycin SV MMX for traveler’s diarrhea in adolescents aged 12-17 is in progress with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traveler Diarrhea

Drugs mentioned

• Rifamycin SV-MMX (rifamycin SV-MMX)

Snippet

Sponsor: RedHill Biopharma Limited | Conditions: Traveler's Diarrhea | Phase 2 | Status: UNKNOWN